SlideShare a Scribd company logo
1 of 1
Download to read offline
14T0900
Comparative Dissolution of Over the Counter (OTC) Acetaminophen
“Fast-Release Quick Gels ” Versus Standard Acetaminophen Tablets.
G. Abernathy, D. Choi, C. Colwell, K. Powell, R. Webb, J.R. Dunbar
South College School of Pharmacy, Knoxville, TN
PURPOSE
METHOD
RESULTS
One of the many acetaminophen products
available OTC, is a 500 mg gelcap formulation
distributed by a major U.S. pharmacy chain that
carries the label descriptor, “Fast-Release Quick
Gels ”. It is reasonable to expect that this
labeling could lead the consumer to infer that this
product is superior to a standard immediate-
release tablet with regard to onset of pain-
relieving action, and overall efficacy. This study
was undertaken to determine the dissolution
profile of these “Fast-Release Quick Gels ”
compared to the standard immediate release
caplet formulation distributed by the same
pharmacy chain; and whether any differences
might be significant enough to justify a
consumer’s assumption that it would be a “faster-
acting” pain-relieving product.
CONCLUSION
REFERENCE &
Acknowledgement
Despite carrying the label
statement, “Fast-Release Quick
Gels ”, the OTC acetaminophen
gelcap formulation, sold by a major
U.S. pharmacy chain, does not
demonstrate a superior rate of
dissolution relative to the their
standard OTC acetaminophen
caplet. While the “Fast-Release”
label designation may be
consistent with the generally
accepted dissolution performance
characteristic of “immediate
release”, the labeling, “Fast-
Release Quick Gels ”, can imply
to the consumer a superior rate of
dissolution than standard
acetaminophen tablets, which was
not demonstrated in this study.
There was no difference in dissolution profiles between the 500 mg acetaminophen gelcaps (“Fast-Release Quick Gels ”)
and the 500 mg acetaminophen caplets when using any common, identical test conditions. Both products exhibited slower
dissolution at 30 vs 50 rpm in both phosphate and SGF media, but still exhibited no difference in dissolution of
acetaminophen between products.
Acetaminophen, 500 mg gelcaps (“Fast-Release
Quick Gels ”) and 500 mg caplets were
purchased from one of the local chain
pharmacies. Dissolution of these products was
tested according to the USP monograph for
acetaminophen tablets using 900mL phosphate
buffer, pH 5.8 @ 37 C; USP 2 apparatus with 50
rpm paddle speed. These products were also
tested by substituting 900mL simulated gastric
fluid w/o enzymes (SGF), pH 1.2 (USP) as the
dissolution media, as well as using both media at
lower paddle speed (30 rpm) to determine if these
varying dissolution conditions might be more or
less discriminating between the two products than
the USP monograph. Dissolution samples taken
at 5, 10, 20, and 30 minutes were analyzed for
acetaminophen concentrations using the
reversed-phase HPLC method described for the
“Assay”, in the USP monograph for
acetaminophen tablets.
1. United States Pharmacopeia
(USP) 39 - National Formulary
(NF) 34. May 1, 2016.
The authors wish to acknowledge
the support of South College
School of Pharmacy for their
continued support of student
research.

More Related Content

Similar to AAPS Poster

DRUG PRODUCT PERFORMANCE, IN VITRO
DRUG PRODUCT PERFORMANCE, IN VITRODRUG PRODUCT PERFORMANCE, IN VITRO
DRUG PRODUCT PERFORMANCE, IN VITROAnkit Malik
 
generic substitution and biowaver
generic substitution and biowavergeneric substitution and biowaver
generic substitution and biowaverSUJITHA MARY
 
Bioequivalence biowaiver and ivivc studies 2014 new
Bioequivalence biowaiver and ivivc studies 2014 newBioequivalence biowaiver and ivivc studies 2014 new
Bioequivalence biowaiver and ivivc studies 2014 newAsra Hameed
 
DESIGN AND EVALUATION OF PULSATILE DRUG DELIVERY SYSTEM CONTAINING PANTOPRAZO...
DESIGN AND EVALUATION OF PULSATILE DRUG DELIVERY SYSTEM CONTAINING PANTOPRAZO...DESIGN AND EVALUATION OF PULSATILE DRUG DELIVERY SYSTEM CONTAINING PANTOPRAZO...
DESIGN AND EVALUATION OF PULSATILE DRUG DELIVERY SYSTEM CONTAINING PANTOPRAZO...Reshma Fathima .K
 
Biopharmaceutic considerations in drug product design and in
Biopharmaceutic considerations in drug product design and inBiopharmaceutic considerations in drug product design and in
Biopharmaceutic considerations in drug product design and inSUJITHA MARY
 
Formulation development and evalution of matrix tablet of
Formulation development and evalution of matrix tablet ofFormulation development and evalution of matrix tablet of
Formulation development and evalution of matrix tablet ofGajanan Ingole
 
The role of dissolution in the demonstration of bioequivalence
The role of dissolution in the demonstration of bioequivalenceThe role of dissolution in the demonstration of bioequivalence
The role of dissolution in the demonstration of bioequivalenceinemet
 
Dissolution test.
Dissolution test.Dissolution test.
Dissolution test.Salum Mkata
 
DRUG DISSOLUTION, BIO-AVAILABILITY AND IVIVC DEVELOPMENT
DRUG DISSOLUTION, BIO-AVAILABILITY AND IVIVC DEVELOPMENTDRUG DISSOLUTION, BIO-AVAILABILITY AND IVIVC DEVELOPMENT
DRUG DISSOLUTION, BIO-AVAILABILITY AND IVIVC DEVELOPMENTRoshan Sonkar
 
Developing a discriminating dissolution
Developing a discriminating dissolutionDeveloping a discriminating dissolution
Developing a discriminating dissolutionV.Maheswaran ,
 
Formulation and Evaluation of Amlodipine Fast Dissolving Tablets
Formulation and Evaluation of Amlodipine Fast Dissolving TabletsFormulation and Evaluation of Amlodipine Fast Dissolving Tablets
Formulation and Evaluation of Amlodipine Fast Dissolving Tabletsijtsrd
 
Study submission of Bioequivalence and Drug review Process, BCS (BIOPHARMACEU...
Study submission of Bioequivalence and Drug review Process, BCS (BIOPHARMACEU...Study submission of Bioequivalence and Drug review Process, BCS (BIOPHARMACEU...
Study submission of Bioequivalence and Drug review Process, BCS (BIOPHARMACEU...Naveen Balaji
 
Bioavailability and Bioequivalence
Bioavailability and Bioequivalence Bioavailability and Bioequivalence
Bioavailability and Bioequivalence Nilesh Kulkarni
 
DEVELOPMENT AND EVALUATION OF ONDANSETRON MEDICATED JELLY
DEVELOPMENT AND EVALUATION OF ONDANSETRON MEDICATED JELLYDEVELOPMENT AND EVALUATION OF ONDANSETRON MEDICATED JELLY
DEVELOPMENT AND EVALUATION OF ONDANSETRON MEDICATED JELLYPARAS POPHALKAR
 

Similar to AAPS Poster (20)

DRUG PRODUCT PERFORMANCE, IN VITRO
DRUG PRODUCT PERFORMANCE, IN VITRODRUG PRODUCT PERFORMANCE, IN VITRO
DRUG PRODUCT PERFORMANCE, IN VITRO
 
generic substitution and biowaver
generic substitution and biowavergeneric substitution and biowaver
generic substitution and biowaver
 
Drug product perfomance in vitro
Drug product perfomance in vitroDrug product perfomance in vitro
Drug product perfomance in vitro
 
Presentation1
Presentation1Presentation1
Presentation1
 
Bioequivalence biowaiver and ivivc studies 2014 new
Bioequivalence biowaiver and ivivc studies 2014 newBioequivalence biowaiver and ivivc studies 2014 new
Bioequivalence biowaiver and ivivc studies 2014 new
 
Claim & Reasonable Probability (Part 2)
Claim & Reasonable Probability (Part 2)Claim & Reasonable Probability (Part 2)
Claim & Reasonable Probability (Part 2)
 
DESIGN AND EVALUATION OF PULSATILE DRUG DELIVERY SYSTEM CONTAINING PANTOPRAZO...
DESIGN AND EVALUATION OF PULSATILE DRUG DELIVERY SYSTEM CONTAINING PANTOPRAZO...DESIGN AND EVALUATION OF PULSATILE DRUG DELIVERY SYSTEM CONTAINING PANTOPRAZO...
DESIGN AND EVALUATION OF PULSATILE DRUG DELIVERY SYSTEM CONTAINING PANTOPRAZO...
 
Biopharmaceutic considerations in drug product design and in
Biopharmaceutic considerations in drug product design and inBiopharmaceutic considerations in drug product design and in
Biopharmaceutic considerations in drug product design and in
 
Formulation development and evalution of matrix tablet of
Formulation development and evalution of matrix tablet ofFormulation development and evalution of matrix tablet of
Formulation development and evalution of matrix tablet of
 
The role of dissolution in the demonstration of bioequivalence
The role of dissolution in the demonstration of bioequivalenceThe role of dissolution in the demonstration of bioequivalence
The role of dissolution in the demonstration of bioequivalence
 
New methods of solubility
New methods of solubilityNew methods of solubility
New methods of solubility
 
Dissolution test.
Dissolution test.Dissolution test.
Dissolution test.
 
DRUG DISSOLUTION, BIO-AVAILABILITY AND IVIVC DEVELOPMENT
DRUG DISSOLUTION, BIO-AVAILABILITY AND IVIVC DEVELOPMENTDRUG DISSOLUTION, BIO-AVAILABILITY AND IVIVC DEVELOPMENT
DRUG DISSOLUTION, BIO-AVAILABILITY AND IVIVC DEVELOPMENT
 
Developing a discriminating dissolution
Developing a discriminating dissolutionDeveloping a discriminating dissolution
Developing a discriminating dissolution
 
Formulation and Evaluation of Amlodipine Fast Dissolving Tablets
Formulation and Evaluation of Amlodipine Fast Dissolving TabletsFormulation and Evaluation of Amlodipine Fast Dissolving Tablets
Formulation and Evaluation of Amlodipine Fast Dissolving Tablets
 
B
BB
B
 
Study submission of Bioequivalence and Drug review Process, BCS (BIOPHARMACEU...
Study submission of Bioequivalence and Drug review Process, BCS (BIOPHARMACEU...Study submission of Bioequivalence and Drug review Process, BCS (BIOPHARMACEU...
Study submission of Bioequivalence and Drug review Process, BCS (BIOPHARMACEU...
 
Bioavailability and Bioequivalence
Bioavailability and Bioequivalence Bioavailability and Bioequivalence
Bioavailability and Bioequivalence
 
Biowaiver
BiowaiverBiowaiver
Biowaiver
 
DEVELOPMENT AND EVALUATION OF ONDANSETRON MEDICATED JELLY
DEVELOPMENT AND EVALUATION OF ONDANSETRON MEDICATED JELLYDEVELOPMENT AND EVALUATION OF ONDANSETRON MEDICATED JELLY
DEVELOPMENT AND EVALUATION OF ONDANSETRON MEDICATED JELLY
 

AAPS Poster

  • 1. 14T0900 Comparative Dissolution of Over the Counter (OTC) Acetaminophen “Fast-Release Quick Gels ” Versus Standard Acetaminophen Tablets. G. Abernathy, D. Choi, C. Colwell, K. Powell, R. Webb, J.R. Dunbar South College School of Pharmacy, Knoxville, TN PURPOSE METHOD RESULTS One of the many acetaminophen products available OTC, is a 500 mg gelcap formulation distributed by a major U.S. pharmacy chain that carries the label descriptor, “Fast-Release Quick Gels ”. It is reasonable to expect that this labeling could lead the consumer to infer that this product is superior to a standard immediate- release tablet with regard to onset of pain- relieving action, and overall efficacy. This study was undertaken to determine the dissolution profile of these “Fast-Release Quick Gels ” compared to the standard immediate release caplet formulation distributed by the same pharmacy chain; and whether any differences might be significant enough to justify a consumer’s assumption that it would be a “faster- acting” pain-relieving product. CONCLUSION REFERENCE & Acknowledgement Despite carrying the label statement, “Fast-Release Quick Gels ”, the OTC acetaminophen gelcap formulation, sold by a major U.S. pharmacy chain, does not demonstrate a superior rate of dissolution relative to the their standard OTC acetaminophen caplet. While the “Fast-Release” label designation may be consistent with the generally accepted dissolution performance characteristic of “immediate release”, the labeling, “Fast- Release Quick Gels ”, can imply to the consumer a superior rate of dissolution than standard acetaminophen tablets, which was not demonstrated in this study. There was no difference in dissolution profiles between the 500 mg acetaminophen gelcaps (“Fast-Release Quick Gels ”) and the 500 mg acetaminophen caplets when using any common, identical test conditions. Both products exhibited slower dissolution at 30 vs 50 rpm in both phosphate and SGF media, but still exhibited no difference in dissolution of acetaminophen between products. Acetaminophen, 500 mg gelcaps (“Fast-Release Quick Gels ”) and 500 mg caplets were purchased from one of the local chain pharmacies. Dissolution of these products was tested according to the USP monograph for acetaminophen tablets using 900mL phosphate buffer, pH 5.8 @ 37 C; USP 2 apparatus with 50 rpm paddle speed. These products were also tested by substituting 900mL simulated gastric fluid w/o enzymes (SGF), pH 1.2 (USP) as the dissolution media, as well as using both media at lower paddle speed (30 rpm) to determine if these varying dissolution conditions might be more or less discriminating between the two products than the USP monograph. Dissolution samples taken at 5, 10, 20, and 30 minutes were analyzed for acetaminophen concentrations using the reversed-phase HPLC method described for the “Assay”, in the USP monograph for acetaminophen tablets. 1. United States Pharmacopeia (USP) 39 - National Formulary (NF) 34. May 1, 2016. The authors wish to acknowledge the support of South College School of Pharmacy for their continued support of student research.